Stephen M. Ansell, MD, PhD, on Progress of CAR T-Cell Therapy
December 12, 2019
The Mayo Clinic expert highlights exciting advancements being made in chimeric antigen receptor T-cell therapy for blood cancer.
Stephen M. Ansell, MD, PhD
Targeting the Tumor Microenvironment in Lymphoma
December 4, 2015
In this interview we discuss the role of the tumor microenvironment in Hodgkin and non-Hodgkin lymphoma and research that seeks to disrupt and target this environment as a means of treatment.
The Era of Immuno-Oncology: Are We There Yet?
March 15, 2015
The next few years hold great promise, as new agents emerge and others consolidate their place on our shelves. We will be forced to rethink strategies and redefine management as a new era of immuno-oncology dawns.
Innate Immune B Cells Gone Bad
November 16, 2011
Normal B lymphocytes can follow either of two functionally distinct pathways of development. The first is a classical germinal center T-dependent pathway in which diversification and maturation generate a delayed but almost unlimited high-affinity response to antigens.
